As of Thursday close, Abbott Laboratories’s (NYSE:ABT) stock was up $0.4, moving up 0.38 percent to $104.93. The average number of shares traded per day over the past five days has been 3,593,380 shares. 2 times new highs have been achieved over the past 5 days, with a $0.19 gain in that time frame. In the last twenty days, the average volume was 4,442,420, while in the previous 50 days, it was 4,862,976.
Since last month, ABT stock retreated -2.19%. Shares of the company fell to $103.67 on 08/08/23, the lowest level in the past month. A 52-week high of $115.83 was reached on 07/24/23 after having rallying from a 52-week low of $93.25. Since the beginning of this year, ABT’s stock price has dropped by -4.43% or -$4.86, and marked a new high 7 times. However, the stock has declined by -9.41% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ABT stock investors should be aware that Abbott Laboratories (ABT) stock had its last reported insider trading activity 10 days ago on Aug 08. Wainer Andrea F, the EXECUTIVE VICE PRESIDENT of the company, disposed of 10,400 shares for $105.03 on Aug 08. It resulted in a $1,092,297 divestment by the insider. STARKS DANIEL J sold 50,000 shares at an average price of $113.76 on Jul 27. The insider now owns 6,775,316 shares following the transaction. On May 02, Director STARKS DANIEL J sold 50,000 shares at $111.02 apiece. The transaction was valued at $5,551,193.
Valuation Metrics
Right now, Abbott Laboratories (ABT) has a P/E ratio of about 35.68. The stock’s beta is 0.67. Besides these, the trailing price-to-sales (P/S) ratio of 4.50, the price-to-book (PB) ratio of 4.91, and the price-to-cash flow ratio of 33.00 may also be considered.
The latest dividend of $0.51 per share was paid out, remained unchanged from last year’s $0.51. On Friday December 9 2022, a $0.04 dividend increase was announced.
Financial Health
In the three months ended June 29, Abbott Laboratories’s quick ratio stood at 1.20, while its current ratio was 1.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.39, and the total debt-to-equity ratio was 0.45. On the profitability front, the trailing twelve-month gross margin is 55.20% percent. In the year ended June 29, operating margins totaled 15.20%. Based on annual data, ABT earned $24.51 billion in gross profit and brought in $43.65 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.00%. Return on equity (ROE) for the past 12 months was 14.10%.
In Abbott Laboratories’s quarter-end financial report for June 29, it reported total debt of $14.56 billion against cash and short-term investments of $320.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ABT’s revenue fell -12.82% to $9.75 billion during the quarter, while net income inched up to $9.98 billion. While analysts expected Abbott Laboratories to report $1.05 quarterly earnings, the actual figure was $1.08 per share, beating the consensus estimate by 2.90%. During the quarter, the company generated $2.34 billion in EBITDA. The liabilities of Abbott Laboratories were 35.95 billion at the end of its most recent quarter ended June 29, and its total debt was $16.99 billion. The value of shareholders’ equity is $1.74 billion.
Technical Picture
This quick technical analysis looks at Abbott Laboratories’s (ABT) price momentum. With a historical volatility rate of 16.34%, the RSI 9-day stood at 35.93% on 17 August.
With respect to its five-day moving average, the current Abbott Laboratories price is up by +0.18% percent or $0.19. At present, ABT shares trade -6.17% below its 20-day simple moving average and +7.02% percent above its 100-day simple moving average. However, the stock is currently trading approximately +2.25% above its SMA50 and +5.47% above its SMA200.
Stochastic coefficient K was 11.34% and Stochastic coefficient D was 13.95%, while ATR was 1.75. Given the Stochastic reading of 13.67% for the 14-day period, the RSI (14) reading has been calculated as 39.66%. As of today, the MACD Oscillator reading stands at -0.74, while the 14-day reading stands at -2.02.
Analyst Ratings
Wolfe Research upgraded its rating on Abbott Laboratories (NYSE: ABT) to a Peer perform in a note to investors on July 21, 2023. The analysts firm previously had an Underperform rating on the stock.Abbott Laboratories (ABT) has been rated Overweight by analysts. According to 0 brokerage firms, ABT is a sell, and 7 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 5 analysts rate Abbott Laboratories stock as buy, with 13 recommending it as overweight.
With a median target price of $123.00, the current consensus forecast for the stock is $112.00 – $136.00. Based on these forecasts, analysts predict Abbott Laboratories (ABT) will achieve an average price target of $124.32.
